JP2019534315A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534315A5 JP2019534315A5 JP2019526565A JP2019526565A JP2019534315A5 JP 2019534315 A5 JP2019534315 A5 JP 2019534315A5 JP 2019526565 A JP2019526565 A JP 2019526565A JP 2019526565 A JP2019526565 A JP 2019526565A JP 2019534315 A5 JP2019534315 A5 JP 2019534315A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical
- patient
- preparation according
- present
- pharmaceutical preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 50
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 32
- 238000010521 absorption reaction Methods 0.000 claims description 21
- 239000003623 enhancer Substances 0.000 claims description 21
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 20
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 claims description 19
- 208000012488 Opiate Overdose Diseases 0.000 claims description 18
- 208000024891 symptom Diseases 0.000 claims description 17
- 239000011780 sodium chloride Substances 0.000 claims description 16
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 15
- GYWMRGWFQPSQLK-OPHZJPRHSA-N (4r,4as,7as,12bs)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol;hydron;chloride Chemical compound Cl.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 GYWMRGWFQPSQLK-OPHZJPRHSA-N 0.000 claims description 14
- 229960000677 nalmefene hydrochloride Drugs 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 12
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 12
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 239000003381 stabilizer Substances 0.000 claims description 11
- 239000007951 isotonicity adjuster Substances 0.000 claims description 10
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims description 3
- 229960005297 nalmefene Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims 3
- 229940124532 absorption promoter Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 26
- 238000000034 method Methods 0.000 description 15
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 9
- 206010038678 Respiratory depression Diseases 0.000 description 9
- -1 alkyl saccharide Chemical class 0.000 description 8
- 239000003401 opiate antagonist Substances 0.000 description 4
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 210000001989 nasopharynx Anatomy 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000022540 Consciousness disease Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010027646 Miosis Diseases 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023112864A JP7730443B2 (ja) | 2016-11-18 | 2023-07-10 | オピオイド過剰摂取を処置するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662424378P | 2016-11-18 | 2016-11-18 | |
| US62/424,378 | 2016-11-18 | ||
| PCT/US2017/060964 WO2018093666A1 (en) | 2016-11-18 | 2017-11-09 | Compositions and methods for the treatment of opioid overdose |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023112864A Division JP7730443B2 (ja) | 2016-11-18 | 2023-07-10 | オピオイド過剰摂取を処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534315A JP2019534315A (ja) | 2019-11-28 |
| JP2019534315A5 true JP2019534315A5 (cg-RX-API-DMAC10.html) | 2020-12-17 |
| JP7312698B2 JP7312698B2 (ja) | 2023-07-21 |
Family
ID=62146061
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019526565A Active JP7312698B2 (ja) | 2016-11-18 | 2017-11-09 | オピオイド過剰摂取を処置するための組成物および方法 |
| JP2023112864A Active JP7730443B2 (ja) | 2016-11-18 | 2023-07-10 | オピオイド過剰摂取を処置するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023112864A Active JP7730443B2 (ja) | 2016-11-18 | 2023-07-10 | オピオイド過剰摂取を処置するための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11458091B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3541386A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP7312698B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN110139651A (cg-RX-API-DMAC10.html) |
| AU (2) | AU2017360910B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3044221A1 (cg-RX-API-DMAC10.html) |
| IL (2) | IL312012A (cg-RX-API-DMAC10.html) |
| RU (1) | RU2769397C2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018093666A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
| WO2018093666A1 (en) | 2016-11-18 | 2018-05-24 | Opiant Pharmaceuticals, Inc. | Compositions and methods for the treatment of opioid overdose |
| JP6941224B2 (ja) | 2018-02-06 | 2021-09-29 | イージス セラピューティクス，エルエルシー | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 |
| US20210220346A1 (en) * | 2018-05-17 | 2021-07-22 | Aegis Therapeutics Llc | Formulations and methods for the prevention of opioid overdose |
| WO2019231993A1 (en) * | 2018-06-01 | 2019-12-05 | Purdue Pharma L.P. | Compositions and methods for opioid overdose rescue |
| US11865112B2 (en) | 2018-11-06 | 2024-01-09 | Purdue Pharma L.P. | Compositions and methods for opioid antagonist delivery |
| US20210401827A1 (en) * | 2018-11-07 | 2021-12-30 | Opiant Pharmaceuticals, Inc. | Methods, parenteral pharmaceutical formulations, and devices for the prevention of opioid overdose |
| CA3134943A1 (en) | 2019-03-26 | 2020-10-01 | Pocket Naloxone Corp. | Devices and methods for delivering pharmaceutical compositions |
| US10729687B1 (en) | 2019-07-09 | 2020-08-04 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| US10653690B1 (en) * | 2019-07-09 | 2020-05-19 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| CA3167312A1 (en) * | 2020-02-07 | 2021-08-12 | Stephen J. Lewis | Compositions and methods for attenuating opioid induced cardio and/or respiratory depression |
| CN115515621A (zh) * | 2020-05-04 | 2022-12-23 | 安福星制药公司 | 胆汁酸及其盐作为药物的经鼻递送的增强剂的安全用途 |
| CN121265577A (zh) | 2020-05-18 | 2026-01-06 | 奥瑞克索股份公司 | 用于药物递送的药物组合物 |
| US20220111162A1 (en) * | 2020-07-29 | 2022-04-14 | Lido Ventures Llc | Apparatus, system, and method for facilitating intranasal treatment of a patient |
| EP4284506A4 (en) * | 2021-02-01 | 2024-12-25 | Clear Scientific, Inc. | SEQUESTRATION COMPOUNDS FOR THE TREATMENT OF SUBSTANCE USE DISORDER AND USES THEREOF |
| US20220387407A1 (en) * | 2021-02-08 | 2022-12-08 | Case Western Reserve University | Compositions and methods for attenuating opioid induced cardio and/or respiratory depression |
| US11278709B1 (en) | 2021-03-12 | 2022-03-22 | Pocket Naloxone Corp. | Drug delivery device and methods for using same |
| CA3227828A1 (en) | 2021-08-04 | 2023-02-09 | Indivior Inc. | Compositions and methods for the treatment of opioid overdose |
| TW202333658A (zh) | 2021-11-25 | 2023-09-01 | 瑞典商奥瑞克索股份公司 | 包含腎上腺素之新穎醫藥組合物 |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
| WO2024010379A1 (ko) * | 2022-07-05 | 2024-01-11 | 주식회사 지투지바이오 | 세마글루타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방성 미립구 제제 및 이의 제조방법 |
| WO2024222920A1 (zh) * | 2023-04-28 | 2024-10-31 | 成都苑东生物制药股份有限公司 | 一种用于鼻内给药的药物制剂及其制备方法 |
| WO2025255416A1 (en) * | 2024-06-05 | 2025-12-11 | TMTRx, Inc. | Fentanyl and fentanyl analogue overdose reversal |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| US4987136A (en) | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
| US4882335A (en) | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
| US4880813A (en) | 1988-07-22 | 1989-11-14 | Baker Cummins Pharmaceuticals, Inc. | Method of treatment for allergic rhinitis |
| US5069895A (en) | 1989-11-09 | 1991-12-03 | Diamond Ivan F | Methods for the treatment of alcohol intoxication and dependence |
| EP0444778A1 (en) | 1990-02-14 | 1991-09-04 | Alcon Laboratories, Inc. | Use of alkyl saccharides to enhance the penetration of drugs |
| US5369095A (en) | 1990-02-14 | 1994-11-29 | Alcon Laboratories, Inc. | Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers |
| US6271240B1 (en) | 1996-05-06 | 2001-08-07 | David Lew Simon | Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals |
| EP1423116A1 (en) | 2001-08-14 | 2004-06-02 | Biotie Therapies Corp. | Method of treating alcoholism or alcohol abuse |
| EP1789075A4 (en) | 2004-08-25 | 2009-07-01 | Uab Research Foundation | ABSORPTION ENHANCER FOR DRUG ADMINISTRATION |
| US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
| US20140162965A1 (en) | 2004-08-25 | 2014-06-12 | Aegis Therapeutics, Inc. | Compositions for oral drug administration |
| US9114069B2 (en) | 2004-08-25 | 2015-08-25 | Aegis Therapeutics, Llc | Antibacterial compositions for drug administration |
| US20110257096A1 (en) | 2004-08-25 | 2011-10-20 | Aegis Therapeutics, Inc. | Compositions for drug administration |
| US8268791B2 (en) | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
| CN1305474C (zh) * | 2004-10-13 | 2007-03-21 | 北京国药龙立生物医药新技术有限公司 | 盐酸纳美芬鼻腔给药制剂 |
| US20070212307A1 (en) | 2006-02-10 | 2007-09-13 | Daniel Wermeling | Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same |
| US20080090771A1 (en) | 2006-10-06 | 2008-04-17 | Shire Llc | Abuse-resistant hydrocodone compounds, compositions and methods of using the same |
| WO2008095086A2 (en) | 2007-01-31 | 2008-08-07 | University Of Virginia Patent Foundation | Topiramate plus naltrexone for the treatment of addictive disorders |
| IL187159A0 (en) | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
| JP2010537990A (ja) | 2007-08-27 | 2010-12-09 | ユニバーシティ オブ バージニア パテント ファウンデーション | アルコール中毒および薬物嗜癖の処置のための医薬の組み合わせ |
| US20090258865A1 (en) | 2008-03-28 | 2009-10-15 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
| WO2009128474A1 (ja) | 2008-04-16 | 2009-10-22 | 財団法人化学及血清療法研究所 | トロンビン固定化生体吸収性シート製剤の製造方法 |
| ES2686299T3 (es) | 2010-10-29 | 2018-10-17 | Troikaa Pharmaceuticals Ltd | Composiciones nasales de vitamina B12 |
| PT3415139T (pt) | 2011-06-14 | 2022-06-20 | Neurelis Inc | Administração de benzodiazepina |
| US10485798B2 (en) | 2012-08-22 | 2019-11-26 | Aptapharma Inc. | Methylnaltrexone nasal formulations, methods of making, and use thereof |
| US20140171458A1 (en) | 2012-12-13 | 2014-06-19 | 3B Pharmaceuticals, Inc. | Intranasal naltrexone |
| DE202013105715U1 (de) | 2013-08-22 | 2014-02-19 | Sipnose Ltd. | Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers |
| EP3057596A4 (en) | 2013-10-14 | 2017-03-29 | Palmaya Pty Ltd | Compositions and methods of administering same |
| WO2015095389A1 (en) * | 2013-12-18 | 2015-06-25 | Aegis Therapeutics, Llc | Compositions for drug administration |
| US9192570B2 (en) | 2013-12-20 | 2015-11-24 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| US9480644B2 (en) | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
| AU2015228541B2 (en) * | 2014-03-14 | 2020-09-03 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
| US9561177B2 (en) | 2014-03-14 | 2017-02-07 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| US10085937B2 (en) | 2014-03-14 | 2018-10-02 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| US20160008277A1 (en) | 2014-07-09 | 2016-01-14 | Lightlake Therapeutics Inc. | Co-packaged drug products |
| US9517307B2 (en) | 2014-07-18 | 2016-12-13 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
| NZ750067A (en) * | 2016-06-24 | 2025-11-28 | Aegis Therapeutics Llc | Compositions, devices, and methods for the treatment of alcohol use disorder |
| CA3043028A1 (en) | 2016-11-09 | 2018-05-17 | Opiant Pharmaceuticals, Inc. | Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions |
| WO2018093666A1 (en) | 2016-11-18 | 2018-05-24 | Opiant Pharmaceuticals, Inc. | Compositions and methods for the treatment of opioid overdose |
| CN106361700A (zh) | 2016-11-25 | 2017-02-01 | 威海恒基伟业信息科技发展有限公司 | 盐酸纳美芬鼻腔给药制剂 |
| US20210220346A1 (en) | 2018-05-17 | 2021-07-22 | Aegis Therapeutics Llc | Formulations and methods for the prevention of opioid overdose |
| US20210401827A1 (en) | 2018-11-07 | 2021-12-30 | Opiant Pharmaceuticals, Inc. | Methods, parenteral pharmaceutical formulations, and devices for the prevention of opioid overdose |
| WO2020132263A1 (en) | 2018-12-20 | 2020-06-25 | Aegis Therapeutics, Inc. | Compositions, devices, and methods for the treatment of overdose and reward-based disorders |
| US20200390691A1 (en) | 2018-12-20 | 2020-12-17 | Aegis Therapeutics, Inc. | Compositions, devices, and methods for the treatment of overdose and reward-based disorders |
-
2017
- 2017-11-09 WO PCT/US2017/060964 patent/WO2018093666A1/en not_active Ceased
- 2017-11-09 IL IL312012A patent/IL312012A/en unknown
- 2017-11-09 US US16/461,354 patent/US11458091B2/en active Active
- 2017-11-09 RU RU2019118465A patent/RU2769397C2/ru active
- 2017-11-09 CN CN201780081719.4A patent/CN110139651A/zh active Pending
- 2017-11-09 JP JP2019526565A patent/JP7312698B2/ja active Active
- 2017-11-09 CA CA3044221A patent/CA3044221A1/en active Pending
- 2017-11-09 IL IL266674A patent/IL266674B2/en unknown
- 2017-11-09 EP EP17871739.3A patent/EP3541386A4/en not_active Withdrawn
- 2017-11-09 AU AU2017360910A patent/AU2017360910B2/en active Active
-
2022
- 2022-08-04 US US17/881,191 patent/US20220387306A1/en not_active Abandoned
-
2023
- 2023-07-10 JP JP2023112864A patent/JP7730443B2/ja active Active
-
2024
- 2024-02-19 AU AU2024201047A patent/AU2024201047A1/en not_active Abandoned
- 2024-06-25 US US18/753,188 patent/US20250127712A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019118465A (ru) | Композиции и способы лечения передозировки опиоидами | |
| US20210077382A1 (en) | Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions | |
| US9629965B2 (en) | Nasal drug products and methods of their use | |
| RU2020112530A (ru) | Назальные готовые лекарственные формы и способы их применения | |
| JP2022088592A (ja) | アルコール使用障害の処置のための組成物、装置、及び、方法 | |
| CN102905689A (zh) | 包含低剂量纳曲酮的液体鼻喷雾 | |
| US20250319081A1 (en) | Compositions, Devices, and Methods for Treating or Preventing Headaches | |
| AU2017379247A1 (en) | Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy | |
| US12622903B2 (en) | Drug products for intranasal administration and uses thereof | |
| JP2020502215A (ja) | Ｔａｓｋ−１およびｔａｓｋ−３チャネル阻害剤を含む医薬剤形、ならびに呼吸障害療法におけるその使用 | |
| JP5828007B2 (ja) | 局所投与型の嚥下障害改善用医薬品 | |
| WO2025255116A1 (en) | Methods of treatment for opioid-induced ventilatory depression and muscle rigidity | |
| US20240408003A1 (en) | Compositions, devices and methods for the treatment of alcohol use disorder | |
| EP2061497A1 (en) | Compositions and methods for treatment of chronic fatigue syndrome and neurodegenerative diseases | |
| WO2014199486A1 (ja) | 嚥下障害改善用医薬品 |